Influences of gender in metabolic syndrome and its components among people living with HIV virus using antiretroviral treatment in Hawassa, southern Ethiopia

BMC Research Notes

Volumn 9, Issue 1, 2016, Pages

  Hirigo, Agete Tadewos ^a   Tesfaye, Demo Yemane ^a  

^a HAWASSA UNIVERSITY   (Ethiopia)

Author keywords

Antiretroviral treatment; Cardiovascular risks; Gender; Metabolic syndrome

Indexed keywords

GLUCOSE BLOOD LEVEL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ANTHROPOMETRY; BLOOD; COMPLICATION; CROSS-SECTIONAL STUDY; DRUG EFFECTS; ETHIOPIA; FEMALE; GLUCOSE BLOOD LEVEL; GROWTH, DEVELOPMENT AND AGING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MALE; METABOLIC SYNDROME X; METABOLISM; ODDS RATIO; PATHOLOGY; PROSPECTIVE STUDY; SEX DIFFERENCE;

ADULT; ANTHROPOMETRY; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD GLUCOSE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; ETHIOPIA; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; METABOLIC SYNDROME X; ODDS RATIO; PROSPECTIVE STUDIES; SEX FACTORS; TRIGLYCERIDES;

EID: 84960171633     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/s13104-016-1953-2     Document Type: Article

References (35)

1. Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, Van Pelt RE, Wang H, Eckel RH. The metabolic syndrome. Endocr Rev. 2008;29:777-822.
2. Rosolova H, Nussbaumerova B. Cardio-metabolic risk prediction should be superior to cardiovascular risk assessment in primary prevention of cardiovascular diseases. EPMA J. 2011;2:15-26.
3. Expert Panel on Detection Evaluation and Treatment of. High blood cholesterol in adults: third Report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106:3143-421.
4. Pao V, Lee GA, Grunfeld C. HIV therapy, metabolic syndrome, and cardiovascular risk. Curr Atheroscler Rep. 2008;10:61-70.
5. Wand H, Calmy A, Carey DL, Samaras K, Carr A, Law MG, Cooper DA, Emery S. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS. 2007;21:2445-53.
6. Zannou DM, Denoeud L, Lacombe K, Amoussou-Guenou D, Bashi J, Akakpo J, Gougounon A, Akondé A, Adé G, Houngbé F, Girard PM. Incidence of lipodystrophy and metabolic disorders in patients starting nonnucleoside reverse transcriptase inhibitors in Benin. Antivir Ther. 2009;14:371-80.
7. Schargrodsky H, Hernández-Hernández R, Champagne BM, Silva H, Vinueza R, Silva Ayçaguer LC, Touboul PJ, Boissonnet CP, Escobedo J, Pellegrini F, Macchia A, Wilson E. Assessment of cardiovascular risk in seven Latin American cities. Am J Med. 2008;121:58-65.
8. Sobieszczyk ME, Hoover DR, Anastos K, Mulligan K, Tan T, Shi Q, Gao W, Hyman C, Cohen MH, Cole SR, Plankey MW, Levine AM, Justman J. Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the womens interagency HIV study. J Acquir Immune Defic Syndr. 2008;48:272-80.
9. Mondy K, Turner OE, Grubb J, Tong S, Seyfried W, Powderly W, Yarasheski K. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis. 2007;44:726-34.
10. Alberti KGM, Zimmet P, Shaw J. Metabolic syndrome - a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med. 2006;23:469-80.
11. Panel on Detection. Evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106:3121-43.
12. Martin LS, Pasquier E, Roudaut N, Vandhuick O, Vallet S, Bellein V, et al. Metabolic syndrome: a major risk factor for atherosclerosis in HIV-infected patients (SHIVA study). Presse Med. 2008;37:579-84.
13. Hansen BR, Petersen J, Haugaard SB, Madsbad S, Obel N, Suzuki Y, Andersen O. The prevalence of metabolic syndrome in Danish patients with HIV infection: the effect of antiretroviral therapy. HIV Med. 2009;10:378-87.
14. Mondy K, Overton ET, Grubb J, Tong S, Seyfried W, Powderly W, Yarasheski K. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis. 2007;44:726-34.
15. Wand H, Calmy A, Carey DL, Samaras K, Carr A, Law MG, Cooper DA, Emery S, Committee ITIC. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS. 2007;21:2445-53.
16. Troian MC, Castilhos C, Castilhos M, Bialeski N. Prevalência de síndrome metabólica e dislipidemia em pacientes HIV-positivos em uso de terapia anti-retroviral. J Bras Med. 2005;89:31-4.
17. Diehl LA, Dias JR, Paes ACS, Thomazini MC, Garcia LR, Cinagawa E, Wiechmann SL, Carrilho AJF. Prevalência da Lipodistrofia Associada ao HIV em Pacientes Ambulatoriais Brasileiros: Relação com Síndrome Metabólica e Fatores de Risco Cardiovascular. Arq Bras Endrocrinol Metab. 2008;52:658-67.
18. Samaras K. Metabolic consequences and therapeutic options in Highly active antiretroviral therapy in human immunodeficiency virus-1 infection. J Antimicrob Chemother. 2007;10:1093-100.
19. Alvarez C, Salazar R, Galindez J, Rangel F, Castaneda ML, Lopardo G, Cuhna CA, Roldan Y, Sussman O, Gutierrez G, Cure-Bolt N, Seas C, Carcamo C, Castrillo M. Metabolic syndrome in HIV-infected patients receiving antiretroviral therapy in Latin America. Braz J Infect Dis. 2010;14:256-63.
20. Baum M, Rafie C, Lai S, Xue L, Sales S, Page JB, Berkman R, Karas L, Campa A. Coronary heart disease (CHD) risk factors and metabolic syndrome in HIV-positive drug users in Miami. Am J Infect Dis. 2006;2:173-9.
21. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using international diabetes foundation and adult treatment panel III criteria. Diabetes Care. 2007;30:113-9.
22. Ivana K, Ariana V, Branka S, Mladen S, Josipa K, Silvije V. Metabolic syndrome in a metapopulation of Croatian island isolates. Croat Med J. 2006;47:585-92.
23. Lauda LG, Mariath AB, Grillo LP. Metabolic syndrome and its components in HIV-infected individuals. Rev Assoc Med Bras. 2011;57:178-81.
24. Dimodi TH, Etame SL, Nguimkeng SB, Mbappe EF, Ndoe EN, Tchinda NJ, Ebene AJ, Ntentié RF, Kingue AB, Angie MM, Paka DG, Kouanfack C, Ngondi LJ, Enyong OJ. Prevalence of metabolic syndrome in HIV-infected Cameroonian patients. World J AIDS. 2014;4:85-92.
25. Lauda LG, Mariath AB, Grillo LP. Metabolic syndrome and its components in HIV-infected individuals. Rev Assoc Med Bras. 2011;57:178-81.
26. Asztalos BF, Schaefer EJ, Horvath KV, Cox CE, Skinner S, Gerrior J, Gorbach SL, Christine Wanke C. Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patients. Atherosclerosis. 2006;184:72-7.
27. Sudano I, Spieker LE, Noll G, Corti R, Weber R, Lüscher TF. Cardiovascular disease in HIV infection. Am Heart J. 2006;151:1147-55.
28. Hsia SH, Pan D, Berookim, Lee ML. A population-based, cross-sectional comparison of lipid-related indexes for symptoms of atherosclerotic disease. Am J Cardiol. 2006;98:1047-52.
29. Berhane T, Yami A, Alemseged A, Yemane T, Hamza L, Kassim M, Deribe K. Prevalence of lipodystrophy and metabolic syndrome among HIV positive individuals on highly active anti-retroviral treatment in Jimma, south west Ethiopia. Pan Afr Med J. 2012;13:1-14.
30. Jacobson DL, Tang AM, Spiegelman D, Thomas AM, Skinner S, Gorbach SL, Wanke C. Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr. 2006;43:458-66.
31. Jericó C, Knobel H, Montero M, Ordoñez-Llanos J, Guelar A, Gimeno JL, Saballs P, López-Colomés JL, Pedro-Botet J. Metabolic syndrome among HIV-infected patients:prevalence, characteristics, and related factors. Diabetes Care. 2005;28(132):137.
32. Mondy K, Overton ET, Grubb J, Tong S, Seyfried W, Powderly W, Yarasheski K. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis. 2007;44:726-73.
33. Kagaruki G, Kimaro G, Mweya C, Kilale A, Mrisho R, Shao A, Kalinga A, Kahwa A, Ngadaya E, Materu G, Mfinanga S, Mayige M. Prevalence and risk factors of metabolic syndrome among individuals living with HIV and receiving antiretroviral treatment in Tanzania. Br J Med Med Res. 2015;5:1317-27.
34. Deedwania PC, Gupta R, Sharma KK, Achari V, Gupta B, Maheshwari A, Gupta A. High prevalence of metabolic syndrome among urban subjects in India: a multisite study. Diabetes Metab Syndr. 2014;8:156-61.
35. Alencastro PR, Fuchs SC, Wolff FH, Ikeda ML, Brandao AB, Barcellos NT. Independent predictors of metabolic syndrome in HIV-infected patients. AIDS Patient Care STDS. 2011;25:627-34.